Tempus AI expanded its cancer diagnostics capabilities by acquiring digital pathology firm Paige for $81.3 million primarily in stock, bolstering its cancer diagnostics and research platforms with advanced AI-driven pathology solutions. Paige’s FDA-authorized prostate cancer diagnostic and research-use products complement Tempus’ offerings, aiming to enable earlier and more precise cancer diagnoses. The acquisition aligns with growth strategies targeting integrated clinical insights across oncology care.